Serious Adverse Events Consortium (SAEC)

Description

The international Serious Adverse Events Consortium (SAEC) is a global, non-profit partnership between leading pharmaceutical companies, the FDA, and academic institutions which plans to identify and validate genetic markers that may help predict which individuals are at risk for serious adverse drug events. The goal of the consortium is to publish a set of predictive SNPs for all drug-related serious adverse events (SAEs), reducing significant patient and economic costs as well as improving the flow of safe and effective medical advances by addressing safety issues of new drugs before they reach the market.